CStone Pharmaceuticals (2616.HK)
Develops cancer-fighting drugs for patients in China and worldwide.
4.35-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-35.5%
The outlook
CStone Pharmaceuticals trades at 4.35, sitting near its 52-week low with the price below both its 50- and 200-day moving averages. Analyst consensus is strongly bullish, with an average price target implying substantial upside from current levels, though the stock currently reflects weak near-term momentum.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +228% vs current price
Analyst price target
~12-month · 4 analysts14.29average target+228.5% vs now
Now 4.35
Low 9.44High 20.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.93B
52-wk high
13.15
52-wk low
4.01
50-day avg
5.43
200-day avg
6.42
Trailing P/E
—